Core Viewpoint - Rongchang Biologics (09995) has seen a stock increase of over 3%, currently at 78.8 HKD, with a trading volume of 98.38 million HKD, following the release of promising clinical trial data for its PD-1/VEGF bispecific antibody RC148 [1] Group 1: Clinical Research and Development - According to Huaxi Securities (002926), the clinical research data for RC148, both as a monotherapy and in combination therapy for non-small cell lung cancer (NSCLC), has demonstrated outstanding clinical efficacy and manageable safety [1] - The early data from the RC148-C001 study has led to the drug receiving Breakthrough Therapy Designation (BTD) in China for the treatment of locally advanced or metastatic NSCLC that has failed prior PD-1/PD-L1 inhibitors and platinum-based chemotherapy [1] - The company is actively advancing its clinical trials, with the Phase II trial for RC148 in combination therapy for first-line NSCLC having completed patient enrollment and plans to initiate a Phase III clinical study [1]

Core Viewpoint - Rongchang Biopharmaceutical (09995) has seen a stock increase of over 3%, currently at 78.8 HKD, with a trading volume of 98.38 million HKD, following the release of promising clinical trial data for its PD-1/VEGF bispecific antibody RC148 in treating non-small cell lung cancer [1] Group 1: Clinical Research and Development - The research report from Huaxi Securities highlights that the clinical data for RC148, both as a monotherapy and in combination therapy, demonstrates significant clinical efficacy and manageable safety, achieving a dual-pathway breakthrough [1] - Based on early data from the RC148-C001 study, the drug has received Breakthrough Therapy Designation (BTD) in China for treating locally advanced or metastatic non-small cell lung cancer that has failed prior PD-1/PD-L1 inhibitors and platinum-based chemotherapy [1] - The company is actively advancing its clinical trials, with the Phase II trial for RC148 in combination therapy for first-line non-small cell lung cancer having completed patient enrollment, and plans to initiate a Phase III clinical study [1]

本文源自：金融界AI电报 港股生物医药概念股回升，荣昌生物(09995.HK)涨超2%，泰格医药(03347.HK)、诺诚健华(09969.HK)、 科伦博泰生物-B(06990.HK)、百济神州(06160.HK)等个股跟涨。 ...

Core Viewpoint - Rongchang Biopharmaceutical (Yantai) Co., Ltd. plans to repurchase shares through centralized bidding, with a total repurchase amount between RMB 20 million and RMB 40 million, aimed at employee stock ownership plans or equity incentives [1][6]. Group 1: Repurchase Plan Details - The repurchase will utilize the company's own funds and/or self-raised funds [1][12]. - The maximum repurchase price is set at RMB 95 per share, which does not exceed 150% of the average trading price over the last 30 trading days prior to the board's decision [1][11]. - The repurchase period is set for 12 months from the date of board approval [3][8]. Group 2: Purpose and Impact - The purpose of the repurchase is to enhance employee motivation, establish a long-term incentive mechanism, and boost investor confidence [6][13]. - The repurchased shares will be used for employee stock ownership plans or equity incentives, and any unused shares after three years will be canceled [1][12]. - The financial impact of the repurchase is minimal, with the maximum repurchase amount representing only 0.67% of total assets and 1.72% of net assets as of September 30, 2025 [12][13]. Group 3: Shareholder and Management Plans - As of the announcement date, major shareholders and management have no plans to reduce their holdings in the next three to six months [3][14]. - The board has authorized management to handle all matters related to the share repurchase, including timing, price, and quantity adjustments as necessary [15][16].

RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由榮昌生物製藥 （煙台）股份有限公司（「本公司」）作出。 茲載列本公司於上海證券交易所網站刊登公告如下，僅供參閱。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 承董事會命 榮昌生物製藥（煙台）股份有限公司 董事長兼執行董事 王威東先生 中國煙台 2025年12月22日 於本公告日期，董事會成員包括執行董事王威東先生、房健民博士、林健先生及 溫慶凱先生；非執行董事王荔強博士及蘇曉迪博士；及獨立非執行董事郝先經先 生、陳雲金先生及黃國濱先生。 * 僅供識別 证券代码：688331 证券简称：荣昌生物 公告编号：2025-058 荣昌生物制药（烟台）股份有限公司 关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及 ...

证券代码：688331 证券简称：荣昌生物 公告编号：2025-058 荣昌生物制药（烟台）股份有限公司 关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：不低于人民币 2,000 万元（含），不超过人民币 4,000 万元 （含）。 ● 回购股份资金来源：公司自有资金和/或自筹资金。 ● 回购股份用途：本次回购的股份拟用于员工持股计划或股权激励，若公司未 能在本次股份回购实施结果暨股份变动公告日后 3 年内使用完毕已回购股份，尚 未使用的已回购股份将予以注销。如国家对相关政策调整，则本回购方案按调整 后的政策实行。 ● 回购股份价格：不超过 95 元/股（含）。该价格不高于董事会通过回购决议 前 30 个交易日公司股票交易均价的 150%。 则存在回购方案无法顺利实施的风险。 2、若在本次回购股份的回购期限内发生对公司股票交易价格产生重大影响的 重大事项，或公司生产经营、财务情况、外部客观情况发生重大变化，或其他导 致公司董事会决定终止本次回购方 ...

格隆汇12月22日丨荣昌生物(688331.SH)公布，公司拟以自有资金和/或自筹资金不低于人民币2000万元 (含)，不超过人民币4000万元(含)回购公司股份。本次回购的股份拟用于员工持股计划或股权激励，若 公司未能在本次股份回购实施结果暨股份变动公告日后 3 年内使用完毕已回购股份，尚未使用的已回购 股份将予以注销。回购股份价格：不超过95元/股(含)。该价格不高于董事会通过回购决议前30个交易日 公司股票交易均价的150%。回购股份方式：以集中竞价交易方式。 ...

从资金流向上来看，当日生物制品板块主力资金净流出2.42亿元，游资资金净流入1.63亿元，散户资金 净流入7885.4万元。生物制品板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 证券之星消息，12月22日生物制品板块较上一交易日下跌0.25%，荣昌生物领跌。当日上证指数报收于 3917.36，上涨0.69%。深证成指报收于13332.73，上涨1.47%。生物制品板块个股涨跌见下表： ...

Investment Rating - The investment rating for the company is "Buy" [4] Core Insights - The company's core products have successfully been included in the 2025 National Medical Insurance Drug List, which is expected to drive sales growth [1][3] - The clinical data for the PD-1/VEGF bispecific antibody RC148 shows promising efficacy and safety in treating non-small cell lung cancer, indicating a significant clinical advantage [2][4] - The management team is experienced, and the company has a strong R&D capability, with a stable pipeline of clinical indications [8] Summary by Sections Event 1 - Two innovative drugs from the company have been successfully included in the 2025 National Medical Insurance Drug List, with one new indication for 泰爱® (Tai'ai) and three renewed indications for both 泰爱® and 爱地希® (Aidiqi) [1] Event 2 - The clinical research data for RC148 in treating non-small cell lung cancer has been disclosed, showing outstanding clinical efficacy and manageable safety [2] Clinical Data - The clinical trial results for RC148 indicate an objective response rate (ORR) of 61.9% for monotherapy and 66.7% for combination therapy, with a disease control rate (DCR) of 100% and 95.2% respectively [4] Financial Projections - Revenue projections for 2025-2027 are adjusted to 27.52 billion, 33.85 billion, and 44.13 billion yuan, reflecting year-on-year growth rates of 60.95%, 22.97%, and 30.40% respectively [8] - The net profit for the same period is projected to improve significantly, with estimates of -7.63 billion, -3.16 billion, and 3.84 billion yuan [8]

Market Overview - The US CPI annual rate decline has led to a rise in US stocks, boosting risk market sentiment [1] - The Hang Seng Index opened higher and closed up 0.75%, with the Hang Seng China Enterprises Index and Hang Seng Tech Index rising by 0.68% and 1.12% respectively [1][2] Sector Performance - Major technology stocks saw collective gains, with Tencent up 1.49%, Kuaishou up 1.45%, and Meituan up 1.28% [4] - Pharmaceutical stocks were active, with WuXi AppTec and other related stocks rising [2] - Gaming stocks continued to rise, with MGM China leading with a 6.6% increase [2][5] - AI-driven demand boosted optical fiber and cable stocks, with Yangtze Optical Fiber rising 12% [2] - Automotive, wind power, education, photovoltaic, insurance, and Apple-related stocks also experienced gains [2] Notable Stock Movements - Xpeng Motors rose 7.65%, Horizon Robotics up 7.04%, and Li Auto up 3.81% [4][10] - Electronic cigarette stocks saw significant increases, with China Tobacco Hong Kong up 6.68% [5] - Chinese brokerage stocks rose, with China International Capital Corporation up over 4% [7] - Intelligent driving concept stocks surged, with Youjia Innovation up 31.22% [8] Weak Performers - Heavy machinery stocks faced declines, with China National Heavy Duty Truck Group down over 6% [13] - Gold and precious metal stocks were weak, with several companies experiencing declines of over 2% [16] - Oil stocks also fell, with China Petroleum & Chemical Corporation down 1.52% [15] Capital Flows - Southbound funds recorded a net purchase of HKD 3.371 billion, with net selling from Shanghai-Hong Kong Stock Connect and net buying from Shenzhen-Hong Kong Stock Connect [18] Market Outlook - CITIC Securities suggests that after a strong performance in September, Hong Kong stocks are undergoing a mid-term adjustment, with quality assets entering a high-value zone [18]